Trial reportProbiotics and antimicrobial proteins2026
Probiotic-Containing Nanofiber-Based Dental Floss Suppresses Subgingival Red Complex Periopathogens: A Randomized Double-Blind Crossover Trial.
Trial report in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07149493 (Probiotic-containing Nanofiber-based Dental Floss Suppresses Subgingival Red Complex Periopathogens), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Probiotic-containing Nanofiber-based Dental Floss Suppresses Subgingival Red Complex Periopathogens: A Randomized Double-blind Crossover Study
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a dental nanofloss containing a probiotic (Ligilactobacillus salivarius; LS-nanofloss) was developed by our team. This study aimed to evaluate: (i) its impact on subgingival plaque accumulation and gingival bleeding, and (ii) retention of selected subgingival periopathogens and the introduced probiotic bacteria, and (iii) its effect on the quantity of red complex periopathogens in the subgingival environment. This randomized, double-blind, crossover trial was conducted in 30 healthy male participants. Each subject underwent professional flossing and subsequently used LS-nanofloss/probiotic-free (control) nanofloss at two separate 14-day periods, always followed by a 14-day wash-out. Clinical assessments (subgingival plaque accumulation and gingival bleeding) were performed at five time points; subgingival plaque samples were collected at seven time points for quantitative analysis of total bacterial DNA, L. salivarius, a cariogenic bacterium Streptococcus mutans, and red complex periopathogens. Both nanofloss types significantly reduced plaque accumulation and gingival bleeding after 14 days (p < 0.05), especially in the anterior regions; these improvements, however, regressed after the wash-out period. L. salivarius DNA was detected in 93.3% of samples after professional flossing, 36.7% after self-flossing, and 13.3% even after the wash-out period. The use of LS-nanofloss was associated with a significant reduction in red complex periopathogens (p < 0.05). The investigated L. salivarius-containing nanofloss proved to be an effective oral hygiene device for subgingival introduction of this probiotic strain. Its application reduced the relative quantity of red complex periopathogens in the subgingival environment, showing potential to prevent the development of periodontitis. The trial was registered retrospectively on 2/9/2025 as NCT07149493.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.